Persephone Biosciences key facts
as of Oct 2026- Developer of equitable precision medicines designed to focus on microbial therapeutics for immuno-oncology applications.
- Persephone Biosciences is valued at approximately $37.3M as of Oct 2026, set at its later-stage round, Oct 2024; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $21.6M across 3 recorded rounds; the latest was Seed Round ($317K) in Feb 2021.
- Notable investors include Y Combinator, Pioneer Fund, Gaingels, Springboard Enterprises, ZhenFund — 31 tracked in total.
- Persephone Biosciences has filed 1 Form D with the SEC, most recently Mar 2021 ($317K sold to 24 investors).
- Status: Privately Held (backing).
Valued at $37.3M at its later-stage round, Oct 2024. Nothing has traded since.
- ·The complete investor list: 31 names
- ·Watch Persephone Biosciences: the Monday email on marks, rounds and moves
Persephone Biosciences funding rounds
3 roundsWho backs Persephone Biosciences
31+Membership and data by Private Market View
Persephone Biosciences valuation
Persephone Biosciences was valued at $37.3 million at its later-stage round in Oct 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Persephone Biosciences raised?
Persephone Biosciences has raised $21.6 million in total; 3 of its rounds are on record, from 2017 on. The largest on record was a $317,000 seed round in Feb 2021.
Persephone Biosciences has filed 1 Form D with the SEC, most recently in Mar 2021 ($317,000 sold to 24 investors).
Persephone Biosciences investors
31 investors are on record for Persephone Biosciences, including Y Combinator, Pioneer Fund, Gaingels and Springboard Enterprises. By type, the record holds 6 venture capital firms. The seed round in Feb 2021 drew 24 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Hinge Bio ($46 million), ParcelBio ($41.2 million) and Solarea Bio ($37 million).
About Persephone Biosciences
Developer of equitable precision medicines designed to focus on microbial therapeutics for immuno-oncology applications. The company's medicines use artificial intelligence and omics techniques on multiple cancer patient gut microbiomes and blood samples to identify microbes needed for normal immune function for population-scale patient data analytics, enabling lab researchers to design microbial drugs that prevent and fight cancer.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2017
- Employees
- 22
- Website
- persephone.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.